Plasminogen activator is involved in the hCG-induced neutrophil extravasation and vasopermeability increase in the rat testis.
The role of proteolytic enzymes in the hCG-induced increase in testicular vasopermeability and neutrophil extravasation was studied using protease inhibitors. An intra-testicular injection of hCG together with incubation medium conditioned by polymorphonuclear leucocytes (PMNs) caused a significant increase in vasopermeability and a coincident extravasation of PMN's from the postcapillary venules in the rat testis. When p-aminobenzamidine, a serine protease inhibitor which inhibits urokinase-type plasminogen activator, was administered together with hCG in the incubation medium, both the permeability increase and PMN extravasation were prevented. Aprotinin, another serine protease inhibitor, and Eglin C, a specific neutrophil elastase and cathepsin G inhibitor were, however, without effect. None of these inhibitors caused any non-specific vascular effects in the testis at the concentrations used. These results support the concept that the hCG-induced increase in vasopermeability in the rat testis is related to extravasation of PMNs and suggest that urokinase-type plasminogen activator is involved in migration of these cells through the postcapillary venular walls.
Department of Anatomy, University of Oulu, Finland.
A K
AK
Loukusa
M
M
Veijola
H
H
Rajaniemi
D000578:Amidines / Q000494:pharmacology*; D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001550:Benzamidines / Q000008:administration & dosage / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects*; D056649:Cathepsin G; D002403:Cathepsins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D002465:Cell Movement / Q000187:drug effects; D006063:Chorionic Gonadotropin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005260:Female; D008297:Male; D009504:Neutrophils / Q000187:drug effects*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors / Q000502:physiology*; D015849:Plasminogen Inactivators; D011506:Proteins; D051381:Rats; D012697:Serine Endopeptidases; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D015843:Serpins; D013737:Testis / Q000187:drug effects*; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000502:physiology*
D000578:Amidines; D001550:Benzamidines; D006063:Chorionic Gonadotropin; D015849:Plasminogen Inactivators; D011506:Proteins; D015842:Serine Proteinase Inhibitors; D015843:Serpins; C028656:eglin proteinase inhibitors; C006500:4-aminobenzamidine; D007611:Aprotinin; D002403:Cathepsins; D010960:Plasminogen Activators; D012697:Serine Endopeptidases; D056649:Cathepsin G; C534097:Ctsg protein, rat; D014568:Urokinase-Type Plasminogen Activator